TY - JOUR
T1 - Risk factors of attacks in neuromyelitis optica spectrum disorders
AU - Akaishi, Tetsuya
AU - Takahashi, Toshiyuki
AU - Fujihara, Kazuo
AU - Misu, Tatsuro
AU - Abe, Michiaki
AU - Ishii, Tadashi
AU - Aoki, Masashi
AU - Nakashima, Ichiro
N1 - Funding Information:
T. Akaishi, T. Takahashi, T. Misu, M. Abe, T. Ishii, and M. Aoki report no disclosures. K. Fujihara received speaker honoraria and travel funding from Bayer, Biogen Japan, Eisai, Mitsubishi Tanabe, Novartis, Astellas, Takeda, Asahi Kasei Medical, Daiichi Sankyo, and Nihon Pharmaceutical and received research support from Bayer, Biogen, Asahi Kasei Medical, The Chemo-Sero-Therapeutic Research Institute, Teva, Mitsubishi Tanabe Pharma, Teijin, Chugai, Ono, Nihon Pharmaceutical, and Genzyme. I. Nakashima received speaker honoraria and travel funding from Mitsubishi Tanabe Pharma, Biogen Japan, and Novartis Pharmaceuticals and received research support from LSI Medience Corporation.
Funding Information:
T. Akaishi, T. Takahashi, T. Misu, M. Abe, T. Ishii, and M. Aoki report no disclosures. K. Fujihara received speaker honoraria and travel funding from Bayer , Biogen Japan , Eisai , Mitsubishi Tanabe , Novartis , Astellas , Takeda , Asahi Kasei Medical , Daiichi Sankyo , and Nihon Pharmaceutical and received research support from Bayer, Biogen, Asahi Kasei Medical, The Chemo-Sero-Therapeutic Research Institute, Teva, Mitsubishi Tanabe Pharma, Teijin, Chugai, Ono, Nihon Pharmaceutical, and Genzyme. I. Nakashima received speaker honoraria and travel funding from Mitsubishi Tanabe Pharma , Biogen Japan , and Novartis Pharmaceuticals and received research support from LSI Medience Corporation .
Publisher Copyright:
© 2020 Elsevier B.V.
PY - 2020/6/15
Y1 - 2020/6/15
N2 - Predisposing factors before the onset of neuromyelitis optica spectrum disorders (NMOSD) have not been systematically evaluated by now. We investigated the detailed pre-onset history in consecutive NMOSD patients. Thirteen of the enrolled 53 NMOSD patients (24.5%) had accompanying autoimmune diseases, such as Sjögren's syndrome. History of malignancy was seen in 8 of the 53 patients (15.1%). Recent history of non-neurological clinical episodes, such as systemic allergic reaction, systemic infection, surgical operation, or traumatic injury, was seen in 23 of the 53 patients (43.4%). NMOSD patients are likely to have pre-onset history of other autoimmune diseases, malignancy, or recent non-neurological systemic conditions, which may predispose or trigger the onset of NMOSD.
AB - Predisposing factors before the onset of neuromyelitis optica spectrum disorders (NMOSD) have not been systematically evaluated by now. We investigated the detailed pre-onset history in consecutive NMOSD patients. Thirteen of the enrolled 53 NMOSD patients (24.5%) had accompanying autoimmune diseases, such as Sjögren's syndrome. History of malignancy was seen in 8 of the 53 patients (15.1%). Recent history of non-neurological clinical episodes, such as systemic allergic reaction, systemic infection, surgical operation, or traumatic injury, was seen in 23 of the 53 patients (43.4%). NMOSD patients are likely to have pre-onset history of other autoimmune diseases, malignancy, or recent non-neurological systemic conditions, which may predispose or trigger the onset of NMOSD.
KW - Autoimmune diseases
KW - Infection
KW - Neuromyelitis optica spectrum disorders
KW - Pre-onset history
KW - Surgical operation
UR - http://www.scopus.com/inward/record.url?scp=85082878036&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85082878036&partnerID=8YFLogxK
U2 - 10.1016/j.jneuroim.2020.577236
DO - 10.1016/j.jneuroim.2020.577236
M3 - Article
C2 - 32279020
AN - SCOPUS:85082878036
VL - 343
JO - Advances in Neuroimmunology
JF - Advances in Neuroimmunology
SN - 0165-5728
M1 - 577236
ER -